Epstein-Barr Virus Induces Adhesion Receptor CD226 (DNAM-1) Expression during Primary B-Cell Transformation into Lymphoblastoid Cell Lines

Epstein-Barr virus (EBV) is a common human herpesvirus that establishes latency in B cells. While EBV infection is asymptomatic for most individuals, immune-suppressed individuals are at significantly higher risk of a form of EBV latent infection in which infected B cells are reactivated, grow unchecked, and generate lymphomas. This form of latency is modeled in the laboratory by infecting B cells from the blood of normal human donors in vitro. In this model, we identified a protein called CD226 that is induced by EBV but is not normally expressed on B cells. Rather, it is known to play a role in aggregation and survival signaling of non-B cells in the immune system. Cultures of EBV-infected cells adhere to one another in “clumps,” and while the proteins that are responsible for this cellular aggregation are not fully understood, we hypothesized that this form of cellular aggregation may provide a survival advantage. In this article, we characterize the mechanism by which EBV induces this protein and its expression on lymphoma tissue and cell lines and characterize EBV-infected cell lines in which CD226 has been knocked out. ABSTRACT Epstein-Barr virus (EBV), an oncogenic herpesvirus, infects and transforms primary B cells into immortal lymphoblastoid cell lines (LCLs), providing a model for EBV-mediated tumorigenesis. EBV transformation stimulates robust homotypic aggregation, indicating that EBV induces molecules that mediate cell-cell adhesion. We report that EBV potently induced expression of the adhesion molecule CD226, which is not normally expressed on B cells. We found that early after infection of primary B cells, EBV promoted an increase in CD226 mRNA and protein expression. CD226 levels increased further from early proliferating EBV-positive B cells to LCLs. We found that CD226 expression on B cells was independent of B-cell activation as CpG DNA failed to induce CD226 to the extent of EBV infection. CD226 expression was high in EBV-infected B cells expressing the latency III growth program, but low in EBV-negative and EBV latency I-infected B-lymphoma cell lines. We validated this correlation by demonstrating that the latency III characteristic EBV NF-κB activator, latent membrane protein 1 (LMP1), was sufficient for CD226 upregulation and that CD226 was more highly expressed in lymphomas with increased NF-κB activity. Finally, we found that CD226 was not important for LCL steady-state growth, survival in response to apoptotic stress, homotypic aggregation, or adhesion to activated endothelial cells. These findings collectively suggest that EBV induces expression of a cell adhesion molecule on primary B cells that may play a role in the tumor microenvironment of EBV-associated B-cell malignancies or facilitate adhesion in the establishment of latency in vivo. IMPORTANCE Epstein-Barr virus (EBV) is a common human herpesvirus that establishes latency in B cells. While EBV infection is asymptomatic for most individuals, immune-suppressed individuals are at significantly higher risk of a form of EBV latent infection in which infected B cells are reactivated, grow unchecked, and generate lymphomas. This form of latency is modeled in the laboratory by infecting B cells from the blood of normal human donors in vitro. In this model, we identified a protein called CD226 that is induced by EBV but is not normally expressed on B cells. Rather, it is known to play a role in aggregation and survival signaling of non-B cells in the immune system. Cultures of EBV-infected cells adhere to one another in “clumps,” and while the proteins that are responsible for this cellular aggregation are not fully understood, we hypothesized that this form of cellular aggregation may provide a survival advantage. In this article, we characterize the mechanism by which EBV induces this protein and its expression on lymphoma tissue and cell lines and characterize EBV-infected cell lines in which CD226 has been knocked out.

[1]  A. Letai,et al.  Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection , 2017, eLife.

[2]  Jeffrey T Leek,et al.  Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.

[3]  Manolis Kellis,et al.  The NF-κB genomic landscape in lymphoblastoid B cells. , 2014, Cell reports.

[4]  M. Smyth,et al.  DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins , 2014, Immunology and cell biology.

[5]  Amy M. Holthaus,et al.  Epstein–Barr Virus Nuclear Antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A , 2013, Proceedings of the National Academy of Sciences.

[6]  S. Dave,et al.  Analysis of Epstein-Barr Virus-Regulated Host Gene Expression Changes through Primary B-Cell Outgrowth Reveals Delayed Kinetics of Latent Membrane Protein 1-Mediated NF-κB Activation , 2012, Journal of Virology.

[7]  John Quackenbush,et al.  Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth , 2011, Proceedings of the National Academy of Sciences.

[8]  M. Rowe,et al.  Epstein-Barr Virus Infection of Polarized Epithelial Cells via the Basolateral Surface by Memory B Cell-Mediated Transfer Infection , 2011, PLoS pathogens.

[9]  S. Dave,et al.  An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells , 2010, Infectious Agents and Cancer.

[10]  M. Luftig,et al.  MDM2-dependent inhibition of P53 is required for Epstein-Barr virus B cell growth transformation and infected cell survival , 2009, Infectious Agents and Cancer.

[11]  G. Bornkamm,et al.  Epstein‐Barr virus and the pathogenesis of Burkitt's lymphoma: More questions than answers , 2009, International journal of cancer.

[12]  L. Staudt,et al.  c-Myc and Rel/NF-κB Are the Two Master Transcriptional Systems Activated in the Latency III Program of Epstein-Barr Virus-Immortalized B Cells , 2009, Journal of Virology.

[13]  J. Gutkind,et al.  Human tumor-associated viruses and new insights into the molecular mechanisms of cancer , 2008, Oncogene.

[14]  A. Rickinson,et al.  Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells , 2006, Proceedings of the National Academy of Sciences.

[15]  Y. Zhang,et al.  Identification and Characterization of the CD226 Gene Promoter* , 2006, Journal of Biological Chemistry.

[16]  S. Honda,et al.  LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell. , 2006, International immunology.

[17]  A. Shibuya,et al.  Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226). , 2005, International immunology.

[18]  L. Moretta,et al.  PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. , 2005, Molecular immunology.

[19]  J. Cohen,et al.  Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Lewis L Lanier,et al.  Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). , 2004, International immunology.

[21]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[22]  F. Luscinskas,et al.  Regulation of Leukocyte Transmigration: Cell Surface Interactions and Signaling Events 1 , 2004, The Journal of Immunology.

[23]  E. Kieff,et al.  NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[25]  Gunther Hartmann,et al.  Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 , 2000, The Journal of Immunology.

[26]  G. Mosialos,et al.  Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB , 1999, Oncogene.

[27]  M. Kersten,et al.  Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. , 1998, Leukemia & lymphoma.

[28]  Jaap M Middeldorp,et al.  Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. , 1997, Journal of clinical pathology.

[29]  T. Mcclanahan,et al.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.

[30]  W. Newman,et al.  Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. , 1994, Journal of immunology.

[31]  A. Rickinson,et al.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes , 1992, Journal of virology.

[32]  P. Lipsky,et al.  The role of CD11a/CD18-CD54 interactions in human T cell-dependent B cell activation. , 1991, Journal of immunology.

[33]  G. M. Taylor,et al.  Expression of LFA‐1 by a lymphoblastoid cell line from a patient with monosomy 21: effects on intercellular adhesion , 1990, Clinical and experimental immunology.

[34]  E. Kieff,et al.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. , 1989, The New England journal of medicine.

[35]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[36]  Michael Loran Dustin,et al.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.

[37]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[38]  Jaap M Middeldorp,et al.  Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. , 2003, Critical reviews in oncology/hematology.

[39]  G. Mosialos,et al.  Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. , 1999, Oncogene.

[40]  Michael Loran Dustin,et al.  The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. , 1987, Annual review of immunology.

[41]  Role of NF- (cid:2) B in Cell Survival and Transcription of Latent Membrane Protein 1-Expressing or Epstein-Barr Virus Latency III-Infected Cells , 2022 .